Lp(a)-Hyperlipoproteinämie - Prof. Dr. Florian Kronenberg (Innsbruck) скачать в хорошем качестве

Lp(a)-Hyperlipoproteinämie - Prof. Dr. Florian Kronenberg (Innsbruck)

Prof. Dr. Florian Kronenberg erläutert die Bedeutung von Diagnostik und Therapie der Lp(a)-Hyperlipoproteinämie zur Prävention und Therapie kardiovaskulärer Erkrankungen. Prof. Dr. Florian Kronenberg ist Direktor der Genetischen Epidemiologie am Department für Genetik der Medizinischen Universität Innsbruck, und Erstautor der Konsensusstatements "Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis" der European Atherosclerosis Society. Impulsvortrag Prof. Kronenberg 02:20 Was ist Lp(a)? 12:30 Ist Lp(a) ein kausaler Risikofaktor? 29:25 Lp(a) zur Risikoabschätzung 31:57 Management des erhöhten Lp(a) 41:03 Fragen und Antworten Das Gespräch wurde am 06.11.2023 geführt. Moderatoren: Prof. Dr. Dr. Stephan Schirmer (Kaiserslautern), Dr. Insa Emrich (Homburg) und Prof. Dr. Gunnar Heine (Frankfurt am Main). Weitere Informationen: Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR, Koschinsky M, Lambert G, Mach F, McNeal CJ, Moriarty PM, Natarajan P, Nordestgaard BG, Parhofer KG, Virani SS, von Eckardstein A, Watts GF, Stock JK, Ray KK, Tokgözoğlu LS, Catapano AL. Eur Heart J 2022 doi: 10.1093/eurheartj/ehac361 Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society. Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR, Koschinsky ML, Lambert G, Mach F, McNeal CJ, Moriarty PM, Natarajan P, Nordestgaard BG, Parhofer KG, Virani SS, von Eckardstein A, Watts GF, Stock JK, Ray KK, Tokgözoğlu LS, Catapano AL. Atherosclerosis 2023 doi: 10.1016/j.atherosclerosis.2023.04.012 Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. Kronenberg F, Kronenberg MF, Kiechl S, Trenkwalder E, Santer P, Oberhollenzer F, Egger G, Utermann G, Willeit J. Circulation 1999 doi: 10.1161/01.cir.100.11.1154 Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ, Steinhagen-Thiessen E, Shapiro MD, Stroes ES, Moriarty PM, Nordestgaard BG, Xia S, Guerriero J, Viney NJ, O'Dea L, Witztum JL; AKCEA-APO(a)-LRx Study Investigators. N Engl J Med 2020 doi: 10.1056/NEJMoa1905239 Lipoprotein(a) Concentration and Risks of Cardiovascular Disease and Diabetes. Gudbjartsson DF et al. J Am Coll Cardiol 2019 doi: 10.1016/j.jacc.2019.10.019 Novel method for quantification of lipoprotein(a)-cholesterol: implications for improving accuracy of LDL-C measurements. Yeang C, Witztum JL, Tsimikas S. J Lipid Res 2021 doi: 10.1016/j.jlr.2021.100053 Lipoprotein(a) Levels at Birth and in Early Childhood: The COMPARE Study. Strandkjær N et al. J Clin Endocrinol Metab 2022 doi: 10.1210/clinem/dgab734. Lipoprotein(a) levels from childhood to adulthood: Data in nearly 3,000 children who visited a pediatric lipid clinic. de Boer LM et al. Atherosclerosis 2022 doi: 10.1016/j.atherosclerosis.2022.03.004 The apolipoprotein(a) size polymorphism is associated with nephrotic syndrome. Kronenberg F, Lingenhel A, Lhotta K, Rantner B, Kronenberg MF, König P, Thiery J, Koch M, von Eckardstein A, Dieplinger H. Kidney Int 2004 doi: 10.1111/j.1523-1755.2004.00418.x. Lipoprotein(a)-Lowering by 50 mg/dL (105 nmol/L) May Be Needed to Reduce Cardiovascular Disease 20% in Secondary Prevention: A Population-Based Study. Madsen CM, ..., Nordestgaard BG. Arterioscler Thromb Vasc Biol 2020 doi: 10.1161/ATVBAHA.119.312951 Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures. Miller WG et al. Clin Chem 2010 doi: 10.1373/clinchem.2009.142810. Lipoprotein (a) and genetic polymorphisms of clotting factor V, prothrombin, and methylenetetrahydrofolate reductase are risk factors of spontaneous ischemic stroke in childhood. Nowak-Göttl U et al. Blood 1999 PMID: 10572079 Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. Nordestgaard BG, Langsted A. J Lipid Res 2016 doi: 10.1194/jlr.R071233 Estimation of the Required Lipoprotein(a)-Lowering Therapeutic Effect Size for Reduction in Coronary Heart Disease Outcomes: A Mendelian Randomization Analysis. Lamina C, Kronenberg F; Lp(a)-GWAS-Consortium. JAMA Cardiol 2019 doi: 10.1001/jamacardio.2019.1041 Temporal Trends in Lipoprotein(a) Concentrations: The Atherosclerosis Risk in Communities Study. Deshotels MR et al. J Am Heart Assoc 2022 doi: 10.1161/JAHA.122.026762 Phase 3 Studien zur Lp(a) Senkung: Lp(a)HORIZON (Pelacarsen) https://classic.clinicaltrials.gov/ct... OCEAN(a) Outcomes (Olpasiran) https://classic.clinicaltrials.gov/ct... Der Lp(a) risk calculator ist unter http://www.lpaclinicalguidance.com kostenfrei abrufbar.